The Pharmacokinetics section includes data regarding slightly lower Olysio exposure in subjects with HCV genotype 1 infection with HIV-1 co-infection compared to subjects with HCV genotype 1 mono-infection. The Microbiology section of the label was updated to include additional data on HCV genotype 4.
The Clinical Studies section was also updated to include trial data from the HCV/HIV co-infected trial and the HCV genotype 4 trials.
Olysio is a HCV NS3/4A protease inhibitor currently approved to treat chronic hepatitis C genotype 1 infection as a component of a combination antiviral treatment regimen.
For more information call (800) 526-7736 or visit Olysio.com.